Clinical Trials Logo

Clinical Trial Summary

Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive episode (MDD).

Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00825019
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 3
Start date September 2003
Completion date December 2004

See also
  Status Clinical Trial Phase
Recruiting NCT02972398 - N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders N/A
Completed NCT00855530 - Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder Phase 3
Completed NCT02829671 - Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas N/A
Recruiting NCT02681822 - Multi-center Imaging Genetics Studies in China
Completed NCT00825058 - Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine Phase 3
Recruiting NCT04497493 - Efficacy of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Major Depressive Disorder N/A
Completed NCT01347138 - Health Care Management for the Elderly in Community Through Screening N/A
Completed NCT01377896 - The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours N/A
Completed NCT02449447 - Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet N/A
Completed NCT06239740 - Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder N/A
Not yet recruiting NCT02942251 - Relapse Predicting Model for First Episode Depression N/A
Recruiting NCT02590185 - MetAbolism vaRiability of VEnLafaxine N/A